Biotech & Medtech Fundraising
Boston Innovation Capital (BIC), member SIPC / FINRA, is an advisory firm that was spun out of Life Science Nation (LSN) in 2015. BIC was founded in order to address an unmet need among early-stage entrepreneurs in the biotech and medtech sectors for tactical, hands-on assistance in packaging technologies and management teams and executing fundraising campaigns. Scientist-entrepreneurs raising capital to bring their assets towards commercialization are faced with few choices when seeking outside help for fundraising. In the past, these choices would include small-scale investment banks, and retired bankers or industry executives who may or may not be associated with a broker-dealer. Most cannot provide the global reach and scale of service that allows an entrepreneur to find a clear and expeditious path to capital. Boston Innovation Capital was created to provide this global service, and to help new life science technologies take the next step towards the market.
Colin Widen, CEO, Boston Innovation Capital
Colin Widen, registered representative, is a seasoned executive with 25 years of sales, trading and portfolio management experience in major investment banks. In 2001, Colin left the institutional world and founded W.A.M. Asset Management, a private equity fund of funds that focused on SBIC private equity funds. After selling the firm to a larger fund of funds, Colin joined Deutsche Bank where he led a team providing consulting services about alternative asset allocation strategies to family offices and smaller endowments and foundations. Colin is a registered representative and holds Series 7, 24, 63 and 82 registrations. His specialties include reconstructing hedge fund portfolios and analyzing private equity holdings.